External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer

External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer

<p>Abstract</p> <p>Background</p> <p>Setting priorities for the funding of new anti-cancer agents is becoming increasingly complex. The funding of adjuvant trastuzumab for breast cancer has brought this dilemma to the fore. In this paper we review external factors that...

Full description

Bibliographic Details
Main Authors:	Fralick John, Fralick Michael, Berry Scott, Gainford M Corona, Dranitsaris George, Booth Christopher M, Sue Joanna, Clemons Mark
Format:	Article
Language:	English
Published:	BMC 2007-06-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/7/110

Similar Items

The Incidence, Management, and Outcome of Inflammatory Breast Cancer
by: FRALICK, JOHN
Published: (2009)

Cardiac Toxicity in Breast Cancer Patients Treated with Adjuvant Trastuzumab
by: Lara Isabel Pires Luís
Published: (2019)

Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer
by: Maksym Sereda, et al.
Published: (2017-01-01)

Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer
by: Waldemar Szpak, et al.
Published: (2017-01-01)

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
by: Sachin S Hingmire, et al.
Published: (2017-01-01)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
by: Qiaoping Xu, et al.
Published: (2021-02-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
by: Erika Matos, et al.
Published: (2016-01-01)

Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer
by: Marinko Tanja, et al.
Published: (2018-02-01)

Effectiveness of adjuvant trastuzumab in daily clinical practice
by: Matos Erika, et al.
Published: (2014-12-01)

Short-course adjuvant trastuzumab in breast cancer: Experience from a tertiary cancer center in rural India
by: Avaronnan Manuprasad, et al.
Published: (2020-01-01)

miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer
by: Boye Schnack Nielsen, et al.
Published: (2014-08-01)

BASAL RESOURCE COMPOSITION AND MACROINVERTEBRATE COMMUNITY STRUCTURE IN TALLGRASS, MIXED-GRASS, AND SHORTGRASS PRAIRIE HEADWATER STREAMS
by: Fralick, Kasey Elizabeth
Published: (2019)

An investigation of direct C-alkylation of 2,4-oxazolidinedione and 5-phenyl-2,4-oxazolidinedione utilizing dialkali salt intermediates
by: Fralick, Elizabeth Ann
Published: (2021)

Yellow Sea thermal structure
by: Fralick, Charles R.
Published: (2014)

Anna Bolena, Maria Stuarda, and Roberto Devereux: a study of Gaetano Donizetti's dramatic style
by: Fralick, Larry W.
Published: (2015)

Feasibility of salmon farming as a small business in British Columbia
by: Fralick, James Edward
Published: (2010)

An anthology of nineteenth-century Russian arias for tenor : A guide to performance /
by: Fralick, Larry Wayne
Published: (1995)

Coming to the edge of the circle : a Wiccan initiation ritual /
by: Bado-Fralick, Nikki
Published: (2000)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01)

Radiation Recall Reaction Induced by Adjuvant Trastuzumab (Herceptin)
by: Caroline Chung, et al.
Published: (2009-01-01)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
by: Sagar Sardesai, et al.
Published: (2020-11-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
by: Ali Hajjar, et al.
Published: (2019-01-01)

Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study
by: Peter Dall, et al.
Published: (2018-01-01)

Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
by: Adamczyk A, et al.
Published: (2018-08-01)

Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
by: L G Zhukova, et al.
Published: (2018-06-01)

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
by: Soares Francisco V, et al.
Published: (2007-08-01)

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer
by: Krishna S. Gunturu, et al.
Published: (2013-03-01)

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology∗
by: Richard M. Steingart, MD, et al.
Published: (2019-09-01)

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
by: Abramson, V., et al.
Published: (2022)

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
by: Davidson M, et al.
Published: (2016-11-01)

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
by: William Leung, et al.
Published: (2016-08-01)

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
by: Helena Earl, et al.
Published: (2020-08-01)

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras
by: Karam Irene, et al.
Published: (2013-01-01)

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
by: María F. Mercogliano, et al.
Published: (2017-12-01)

Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Raymond Pierre Abratt
Published: (2017-08-01)

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
by: Wenjin Yin, et al.
Published: (2011-01-01)

Fucose-containing fraction of Reishi in combination with trastuzumab for treatment of trastuzumab resistance human breast cancer cells
by: Jia-Jung Hsu, et al.
Published: (2012)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
by: Nadine Norton, et al.
Published: (2018-06-01)